REHOVOT, Israel, Aug. 25, 2016 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (NASDAQ:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced financial results for the second quarter ended June 30, 2016 and provided a corporate update.
“We have been very productive in recent months advancing our clinical programs and moving closer toward our goal of providing a less invasive, continuous levodopa delivery treatment option for patients suffering from Parkinson’s disease,” said Oded Lieberman, PhD, CEO of NeuroDerm. “We announced that Trial 005, evaluating ND0612H to DUODOPA® in a head-to-head pilot pharmacokinetic study, achieved comparable results in patients with severe Parkinson’s disease. In addition, we have commenced enrolling patients in three important clinical trials: our first clinical trial for ND0701 (trial 101), our continuous, subcutaneously delivered liquid apomorphine-base formulation; a Phase II trial of ND0612H (trial 006) for severe Parkinson’s disease; and a Phase III trial of ND0612L (trial 007, named the “iNDiGO” trial) in patients with moderate Parkinson’s disease. We look forward to meeting with the FDA in late October to discuss our clinical development program and plan to hold a similar meeting with the EMA later this year,” concluded Dr. Lieberman.
“We have been very productive in recent months advancing our clinical programs and moving closer toward our goal of providing a less invasive, continuous levodopa delivery treatment option for patients suffering from Parkinson’s disease,” said Oded Lieberman, PhD, CEO of NeuroDerm. “We announced that Trial 005, evaluating ND0612H to DUODOPA® in a head-to-head pilot pharmacokinetic study, achieved comparable results in patients with severe Parkinson’s disease. In addition, we have commenced enrolling patients in three important clinical trials: our first clinical trial for ND0701 (trial 101), our continuous, subcutaneously delivered liquid apomorphine-base formulation; a Phase II trial of ND0612H (trial 006) for severe Parkinson’s disease; and a Phase III trial of ND0612L (trial 007, named the “iNDiGO” trial) in patients with moderate Parkinson’s disease. We look forward to meeting with the FDA in late October to discuss our clinical development program and plan to hold a similar meeting with the EMA later this year,” concluded Dr. Lieberman.
